Pazopanib (Votrient, GlaxoSmithKline), recently approved by the United States Food and Drug Administration (FDA) for the treatment of patients with advanced renal cell carcinoma (RCC) ([GlaxoSmithKline, 2009](#bib10){ref-type="other"}), is an oral angiogenesis inhibitor targeting vascular endothelial growth factor receptors-1, -2, and -3; platelet-derived growth factor receptors-*α* and -*β*; and the stem cell factor receptor, c-kit ([Sonpavde and Hutson, 2007](#bib29){ref-type="other"}). It is currently under clinical development for the treatment of multiple tumour types ([Altorki *et al*, 2008](#bib2){ref-type="other"}; [Friedlander *et al*, 2008](#bib9){ref-type="other"}; [Sleijfer *et al*, 2009](#bib28){ref-type="other"}; [Taylor *et al*, 2009](#bib34){ref-type="other"}; [Sternberg *et al*, 2010](#bib30){ref-type="other"}). Clinical meaningful efficacy was observed in pazopanib-treated patients with RCC ([Hutson *et al*, 2010](#bib12){ref-type="other"}; [Sternberg *et al*, 2010](#bib30){ref-type="other"}). The safety profile of pazopanib was generally acceptable and tolerable. The most common adverse events were diarrhoea, hypertension, hair colour changes, nausea, anorexia, and vomiting ([Sternberg *et al*, 2010](#bib30){ref-type="other"}). Elevations of liver transaminases were the most common treatment-emergent laboratory abnormalities ([Sternberg *et al*, 2010](#bib30){ref-type="other"}). Elevations in alanine aminotransferase (ALT) \>3 × upper limit of the normal range (ULN) occurred in 18% of the pazopanib-treated RCC patients. Isolated elevations of total bilirubin (TBL) \>1.5 × ULN were seen in 17% of pazopanib-treated RCC patients. Elevations in liver enzymes were generally asymptomatic and reversible and concurrent elevations in both ALT and bilirubin were rare. As the aetiology and mechanism of liver enzyme elevation in pazopanib-treated patients remain unknown, recommended management guideliness are based on analysis of data from clinical trials.

Treatment-associated elevations in transaminases and bilirubin have been reported with other tyrosine kinase inhibitors including sunitinib, lapatinib, and erlotinib ([Motzer *et al*, 2007](#bib21){ref-type="other"}; [Loriot *et al*, 2008](#bib18){ref-type="other"}; [Ryan *et al*, 2008](#bib25){ref-type="other"}), and the incidence varies with agent. It is possible that these treatment-associated elevations in liver enzymes observed with tyrosine kinase inhibitors reflect overlapping on-target and off-target class effects; however, specific mechanisms remain to be elucidated. Abnormalities in clinical liver chemistry measurements are important safety signals for liver injury and may lead to treatment discontinuation, thereby compromising the potential treatment benefit to the patient. Understanding the underlying mechanisms of liver chemistry abnormalities may enable better interpretation and clinical management of these safety signals, and in appropriate circumstances, allow patients to benefit from continued anticancer treatment.

We sought to identify genetic markers in selected candidate genes involved in pazopanib metabolism and pharmacodynamics that may predict risk of ALT and/or bilirubin elevation on treatment. Pazopanib is a substrate for p-glycoprotein and breast cancer-resistant protein, an inhibitor of the human uptake transporter OATP1B1, and an inhibitor of uridine-diphosphoglucuronate glucuronosyltransferase 1A1 (UGT1A1). It is predominately metabolised by CYP3A4 with a minor contribution from CYP2C8 and CYP1A2. Functional polymorphisms in these genes as well as in pazopanib target genes were evaluated using data from two clinical studies that evaluated the efficacy and safety of pazopanib in patients with advanced metastatic RCC ([Hutson *et al*, 2010](#bib12){ref-type="other"}; [Sternberg *et al*, 2010](#bib30){ref-type="other"}).

Materials and Methods
=====================

The protocol and informed consent forms were reviewed and approved by Institutional Review Boards/Independent Ethics Committees according to local guidelines. Clinical studies were conducted in accordance with the Declaration of Helsinki. Written informed consent for participation in the clinical studies was obtained from all patients, and an additional informed consent for pharmacogenetics (PGx) research was obtained for participation in the genetic study.

Patients
--------

The phase II RCC study (VEG102616, Study 1) had 225 participants ([Hutson *et al*, 2010](#bib12){ref-type="other"}) and the phase III RCC study (VEG105192, Study 2) had 435 participants ([Sternberg *et al*, 2010](#bib30){ref-type="other"}). All patients from Study 1 and 290 patients from Study 2 received pazopanib (800 mg daily); the remaining 145 patients in Study 2 were randomised to the placebo arm. To minimise the effect of genetic heterogeneity among ethnic groups on the statistical analyses, the present PGx analyses were performed using the self-reported 'white\' patients of European heritage, which represented the largest subgroup in each of the clinical studies. There were 156 self-reported white patients in Study 1, of whom 116 provided written informed consent for genetic research and had sufficient DNA for genotyping. There were 204 self-reported white patients in Study 2 who received pazopanib, of whom 130 provided written informed consent for genetic research and had sufficient DNA for genotyping. The present PGx analysis population, therefore, consisted of data from the 116 white patients from Study 1 and 130 white patients from Study 2 who received pazopanib and had genotypic data for at least one of the genetic markers evaluated ([Figure 1](#fig1){ref-type="fig"}).

Liver chemistry measurements
----------------------------

Alanine aminotransferase and bilirubin measurements were performed by local institutional laboratories. Both ALT and TBL values were converted to ULN by dividing the laboratory value by the institutional ULN. None of the patients from either study had a baseline ALT level \>3 × ULN or baseline bilirubin level \>1.5 × ULN.

Genetic polymorphisms and genotyping
------------------------------------

Twenty-eight genetic polymorphisms in 11 genes involved in the pharmacokinetics and pharmacodynamics of pazopanib were selected ([Table 1](#tbl1){ref-type="table"}). The selection was based on reported associations or assumed functional changes of the polymorphisms to the expression or activity of the proteins.

The DNA was extracted from blood using the Qiagen (Valencia, CA, USA) QiAmp DNA Blood kit. The *UGT1A1* TA-repeat polymorphism (rs8175347) was genotyped using the FDA-approved Third Wave Invader Assay, which called two alleles: the TA6 (^\*^1) allele and the TA7 (^\*^28) allele. In the rare instance when a patient had a TA-repeat number that was not 6 or 7 (\<1%), the genotype call for that patient was treated as missing data. The remaining polymorphisms were genotyped using Illumina (San Diego, CA, USA) GoldenGate platform ([Fan *et al*, 2003](#bib8){ref-type="other"}), a single base chain extension assay modified by GlaxoSmithKline (Research Triangle Park, NC, USA) ([Taylor *et al*, 2001](#bib33){ref-type="other"}), TaqMan SNP Genotyping assays (Applied Biosystems, Foster City, CA, USA; [Livak *et al*, 1995](#bib17){ref-type="other"}), or sequencing.

*In vitro* UGT1A1 inhibition
----------------------------

The activity of human UGT1A1 was measured in the absence and presence of pazopanib. Human UGT1A1 Supersomes (BD Gentest, BD Biosciences, San Jose, CA, USA) were preincubated in duplicate for 5 min at 37°C in the presence of the pore-former alamethicin, the UGT1A1 substrate 7-hydroxy-4-(trifluoromethyl) coumarin (HFC), and pazopanib concentrations ranging from 0 to 250 *μ*[M]{.smallcaps}. At the end of preincubation, the enzymatic reaction was initiated by adding the cofactor uridine 5′-diphosphoglucuronic acid (UDPGA). The reaction was terminated after an additional 10 min by adding acetonitrile/acetic acid (94/6 \[v/v\]), followed by centrifugation to sediment-precipitated protein. The production of the HFC metabolite 4-trifluoromethylumbelliferyl glucuronide (HFC-gluc) in each supernatant was quantified by HPLC-UV, and the half-maximal inhibitory concentration (IC~50~) value for inhibition of UGT1A1 activity was determined. Incubations without pazopanib were performed in the presence and absence of UDPGA to confirm production of the UDPGA-dependent glucuronide metabolite HFC-gluc. Incubations without probe substrate (HFC) were performed to determine any potential assay interference by pazopanib. The IC~50~ of curcumin, a positive-control inhibitor, was determined in parallel incubations in which pazopanib was replaced with appropriate concentrations of curcumin.

*In vitro* OATP1B1 inhibition
-----------------------------

Inhibition of uptake of the OATP1B1 probe substrate \[^3^H\]-estradiol 17*β*-[D]{.smallcaps}-glucuronide (\[^3^H\]-EG) by pazopanib was measured using a stably transfected CHO cell line. The CHO-OATP1B1 cells were cultured to confluency, trypsinised, and seeded into 24-well assay plates (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) at a density of 70 000 cells cm^--2^ in Dulbecco\'s Modified Eagle Medium (DMEM) with GlutaMAX, 10% (v/v) foetal bovine serum, 0.5% (v/v) penicillin/streptomycin 10 000 units ml^--1^, 0.1% (v/v) [L]{.smallcaps}-proline 50 mg ml^--1^, and 0.7% (v/v) geneticin 50 mg ml^--1^. The cell monolayers were used 2 days after seeding and induced for at least 24 h before use with the addition of DMEM containing sodium butyrate (final concentration, 5 m[M]{.smallcaps}). In the inhibition studies, CHO-OATP1B1 monolayers were preincubated (37°C) for 15--30 min in 1 ml of Dulbecco\'s Phosphate-Buffered Saline (DPBS) with the appropriate concentration of pazopanib. Triplicate wells were used for each concentration of test compound. After removal of preincubation solution, 400 *μ*l of DPBS containing the radiolabelled probe substrate and the appropriate concentrations of pazopanib was added to the wells and the cells were incubated at 37°C for 5 min. The solution was then removed and the wells rinsed rapidly three times using 800 *μ*l cold (4°C) DPBS before solubilisation with 500 *μ*l of 1% (v/v) Triton X-100. Total radioactivity was determined by scintillation counting.

Statistical analysis
--------------------

The data were analysed both as continuous variables in a quantitative trait analysis (QTA) and as discrete values according to predefined thresholds in a case--control analysis. All analyses were performed in SAS version 9.1.3 (SAS Institute, Cary, NC, USA). The QTA was performed using an analysis of covariance model to assess the effect of genetic factors on baseline, maximum on-treatment, and change from baseline (delta) values for ALT and TBL. In the analyses of maximum on-treatment ALT and maximum on-treatment TBL, baseline was included in the model as a covariate. A log~10~-transformation was performed on the ALT and TBL values and a rank transformation was performed on the change-from-baseline values to correct for skewness of the data.

For case--control association analysis, a patient was defined as an ALT 'case\' if one or more ALT measurements were ⩾3 × ULN during dosing with pazopanib. A patient was classified as an ALT 'control\' if all ALT measurements were within the normal range (⩽1 × ULN). A patient was defined as a TBL 'case\' if one or more TBL measurements were ⩾1.5 × ULN during exposure to pazopanib, and a TBL 'control\' if all measurements were within the normal range (⩽1 × ULN). The effect of a genetic polymorphism on ALT or TBL was assessed using Fisher\'s exact test.

The initial exploratory analysis was performed using data from the phase II study (Study 1; VEG102616) and the replication analysis was conducted using data from the phase III study (Study 2; VEG105192). Correction for multiple tests was not performed. Instead, a threshold of *P*\<0.01 was used to determine statistical significance in each study. A marker was 'replicated\' when it was identified to be statistically significant in Study 1 followed by replication in Study 2. For replicated markers, a combined analysis using data from both studies was carried out to evaluate the overall effect.

Results
=======

Demographic and baseline characteristics for patients included in the present PGx investigation from Study 1 and Study 2 are shown in [Table 2](#tbl2){ref-type="table"}. None of the patients included in the PGx analysis had a baseline ALT level \>3 × ULN or baseline bilirubin level \>1.5 × ULN. Exploratory analyses of the effects of the 28 genetic polymorphisms on maximum ALT and bilirubin were first examined using data from Study 1. None of the markers were significantly associated with maximum ALT (*P*\<0.01), and three markers in the *UGT1A1* and *CYP1A2* loci were significantly associated with maximum bilirubin (*P*\<0.01). The markers from the *UGT1A1* locus were the TA-repeat polymorphism (*UGT1A1*^\*^28) and the --3279T/G polymorphism (*UGT1A1*^\*^60), and the marker from the *CYP1A2* locus was the --163C/A polymorphism ([Table 1](#tbl1){ref-type="table"}).

Replication analyses of the three significant TBL markers identified in Study 1 were performed using data from Study 2. Only the TA-repeat polymorphism from the *UGT1A1* gene was replicated (*P*\<0.01). This polymorphism was not associated with maximum ALT measurements in either study.

Data from both studies were subsequently combined to determine the overall effect of the *UGT1A1* TA-repeat polymorphism on bilirubin levels. Of the 246 patients included in this PGx analysis, data for bilirubin and the *UGT1A1* TA-repeat marker were obtained for 236 patients ([Figure 1](#fig1){ref-type="fig"}). Of the remaining 10 patients, 5 had missing *UGT1A1* genotype data and 5 had missing log~10~-transformed maximum or baseline TBL data. As expected, a significant association between the *UGT1A1* TA-repeat polymorphism and maximum bilirubin was observed (*P*=1.6 × 10^−6^ and *P*=1.8 × 10^−8^ for the QTA and case--control analysis, respectively). The median values of maximum bilirubin were 0.75 × ULN, 0.87 × ULN, and 1.40 × ULN for patients with the TA6/TA6, TA6/TA7, and TA7/TA7 genotypes, respectively. Moreover, this polymorphism was significantly associated with bilirubin increases from baseline (delta) during pazopanib treatment (*P*=4.5 × 10^−5^). The median bilirubin increases were 0.31 × ULN, 0.37 × ULN, and 0.71 × ULN for pazopanib-treated patients with the TA6/TA6, TA6/TA7, and TA7/TA7 genotypes, respectively. Thus, the median on-treatment bilirubin increase for TA7 homozygotes was 2.3-fold greater than the increase observed for the TA6 homozygotes ([Figure 2](#fig2){ref-type="fig"}).

Compared with the TA6/TA6 and TA6/TA7 genotypes, the odds ratio (95% confidence interval), positive predictive value, and negative predictive value for TA7/TA7 genotype were 13.1 (5.3--32.2), 0.49, and 0.90, respectively. The incidence of hyperbilirubinemia was 49% (18 of 37) for patients with the TA7/TA7 genotypes and 12% (14 of 113) for patients with the TA6/TA7 genotypes ([Figure 3](#fig3){ref-type="fig"}). In contrast, pazopanib-related incidence of hyperbilirubinemia was only 7% (6 of 86) for patients with the TA6/TA6 genotype. Of the 38 cases of TBL elevation, 32 patients (84%) were either TA7 homozygotes (*n*=18, 47%) or TA7 heterozygotes (*n*=14, 37%).

The ability of pazopanib to inhibit the two major determinants of serum bilirubin levels, UGT1A1 and OATP1B1, was measured. Pazopanib was shown to be a potent inhibitor of UGT1A1 as well as OATP1B1, with IC~50~ of 1.2 and 0.79 *μ*[M]{.smallcaps}, respectively ([Figure 4](#fig4){ref-type="fig"}).

Discussion
==========

This study shows that both maximum on-treatment bilirubin concentration and bilirubin increase from baseline were strongly associated with the *UGT1A1* TA-repeat polymorphism. None of the genetic markers evaluated were predictive of ALT elevation. Bilirubin is metabolised by UGT1A1 for elimination. The *UGT1A1* genetic variant TA7 is known to cause reduced expression of UGT1A1 ([Bosma *et al*, 1995](#bib5){ref-type="other"}), and the TA7/TA7 (^\*^28/^\*^28) genotype predisposes individuals to Gilbert\'s syndrome, a benign form of episodic jaundice ([Bosma *et al*, 1995](#bib5){ref-type="other"}; [Raijmakers *et al*, 2000](#bib23){ref-type="other"}). This *UGT1A1* TA-repeat polymorphism has also been reported to be associated with hyperbilirubinemia induced by several drugs, such as tranilast, nilotinib, and indinavir ([Zucker *et al*, 2001](#bib36){ref-type="other"}; [Danoff *et al*, 2004](#bib7){ref-type="other"}; [Singer *et al*, 2007](#bib27){ref-type="other"}). Pazopanib is a potent inhibitor of UGT1A1 activity *in vitro*, with an IC~50~ of 1.2 *μ*[M]{.smallcaps}. Thus, this study suggests that pazopanib-induced hyperbilirubinemia may be the result of inhibition of UGT1A1 activity combined with genetic defects of the *UGT1A1* gene. This would presumably result in higher levels of unconjugated hyperbilirubinemia, usually associated with a benign clinical course. It is possible that bilirubin elevation associated with other tyrosine kinase inhibitors such as sunitinib, lapatinib, and erlotinib may also be related to *UGT1A1* genotype. However, to our knowledge, data from genetic investigations for drug-induced hyperbilirubinemia for these compounds are not yet available.

We observed that 6 (16%) of the 38 patients who had isolated hyperbilirubinemia had the TA6/TA6 genotype, suggesting that additional factors may contribute to bilirubin elevation in pazopanib-treated patients. Concurrent elevations of transaminases were not seen in these six patients. A recent genome-wide association study identified *OATP1B1* (alternative symbol *SLCO1B1*) as one of the top loci associated with bilirubin levels ([Johnson *et al*, 2009](#bib13){ref-type="other"}). Genetic markers in the *OATP1B1* gene were also evaluated in this study and were not found to be associated with pazopanib-related bilirubin elevation. As pazopanib is also a potent inhibitor of OATP1B1 (*in vitro*), we cannot exclude the possibility that pazopanib-induced hyperbilirubinemia may be the result of inhibition of both OATP1B1 and UGT1A1 activity combined with genetic defects of the *UGT1A1* gene. The lack of association with genetic markers in the *OATP1B1* gene may stem from the fact that pazopanib inhibited hepatic uptake of bilirubin to the same level in both wild type and variant forms.

Among the 246 patients evaluated in this study, concurrent elevation of ALT and bilirubin was observed in one patient (0.4%). This patient was heterozygous (TA6/TA7) for the *UGT1A1* TA-repeat polymorphism and had direct bilirubin of 0.5 mg l^--1^, representing 22% of TBL (2.3 mg dl^--1^). Reduced UGT1A1 activity, both as a result of pazopanib inhibition of UGT1A1 and the genetic defect of the *UGT1A1* gene, may have contributed to the bilirubin elevation observed in this patient. Concurrent elevations in ALT and bilirubin levels after pazopanib treatment could indicate liver toxicity ([Kaplowitz, 2006](#bib15){ref-type="other"}); therefore, it is important to rule out this possibility to allow continued treatment. This is particularly important because continued anticancer treatment may allow for more favourable clinical outcomes and should be feasible in patients with benign hyperbilirubinemia, as might be the case for most pazopanib-treated patients. It follows that, for each patient, the clinical management of hepatotoxicity needs to be tailored according to the severity and impact of this adverse effect on the patient. In addition, the mechanisms involved in the observed elevation in transaminases and bilirubin should also be considered.

This study focused on data from trials evaluating pazopanib monotherapy in patients with RCC. The observed elevation in ALT or bilirubin levels was not associated with liver metastasis for patients included in the present PGx analysis. The full implications of these findings for regimens combining pazopanib with other agents are currently unknown. Clearly, it is important for clinicians to be aware of potential drug--drug interactions, particularly with compounds known to be metabolised and eliminated predominantly through the UGT1A1 pathway. Therefore, concomitant administration of pazopanib and UGT1A1 substrates that have narrow therapeutic index should be undertaken with caution. Pazopanib itself is not known to be subject to significant glucuronidation by UGT1A1. It is, therefore, unlikely that defective UGT1A1 would have a direct impact on the exposure of pazopanib and, therefore, exposure-related toxicities.

The practical implication of our finding is for clinicians to recognise that isolated hyperbilirubinemia in pazopanib-treated patients, after exclusion of other causes such as haemolysis, seems to have a benign aetiology. Given the life-threatening nature of cancer and the benign clinical course of unconjugated hyperbilirubinemia, the data do not call for population-based prospective *UGT1A1* screening to exclude patients from pazopanib monotherapy. Bilirubin fractionation should be conducted in patients who develop hyperbilirubinemia during pazopanib treatment, which could distinguish unconjugated hyperbilirubinemia from conjugated hyperbilirubinemia. The latter would require further investigation. This may help to elucidate the nature of the bilirubin elevation and might enable differentiation of the risk of progression of drug-induced liver injury. A limitation of this study is the lack of bilirubin fractionation data to allow full assessment between the *UGT1A1* polymorphism and unconjugated bilirubin levels.

We thank the investigators and their patients who made this study possible. We acknowledge Leigh Ragone, Morlisa Dixon, Bo Zheng, Nan Bing, and Keith Nangle for their excellent technical support. We thank Melissa Stutts, Vicki Goodman, Theresa Bryant, and Chris Abissi for their contribution in evaluating patients with potential hepatotoxicity; Lauren McCann and Shawn Liu for discussion of the laboratory liver chemistry data. We are grateful to Rafael Amado, Pamela StJean, Matthew Nelson, Anne Marie Martin, and Howard Ball, and the GSK hepatotoxicity board, in particular Christine Hunt and Beena Koshy, for their review and discussion of the data. Financial support for this study and medical editorial assistance was provided by GlaxoSmithKline Pharmaceuticals, Philadelphia, Pennsylvania. We thank Jerome Sah, PhD, ProEd Communications, Inc., for his medical editorial assistance with this manuscript.

![Patient disposition. Of the 225 pazopanib-treated patients in Study 1 (VEG102616) and the 290 pazopanib-treated patients in Study 2 (VEG105192), 112 and 124 patients, respectively, were included in the *UGT1A1* pharmacogenetics (PGx) analysis. These patients were self-reported to be white, provided consent for the PGx analysis, had sufficient DNA for genotyping and valid genotypic data for the *UGT1A1* TA-repeat polymorphism, and had baseline and on-treatment total bilirubin (TBL) data.](6605653f1){#fig1}

![The distribution of baseline total bilirubin (TBL) and maximum TBL by *UGT1A1* TA-repeat genotype for pazopanib-treated white patients from both Study 1 and Study 2. The maximum bilirubin value for one patient who had the TA7/TA7 genotype was truncated from 19 × upper limit of normal (ULN) to 6 × ULN for viewing purposes. The number of patients with each genotype, and the median values for baseline TBL, maximum TBL, and maximum change-from-baseline (delta) TBL are provided. The variation in baseline TBL, maximum TBL, and change-from-baseline TBL by genotype is statistically significant for each end point: *P*=4.0 × 10^−3^, 1.6 × 10^−6^, and 4.5 × 10^−5^, respectively.](6605653f2){#fig2}

![Cumulative incidence of hyperbilirubinemia (⩾1.5 × upper limit of normal \[ULN\]) by *UGT1A1* TA-repeat genotype for pazopanib-treated white patients from both Study 1 and Study 2. The cumulative incidence of total bilirubin (TBL) ⩾1.5 × ULN for each genotype group at a time point (weeks) is the proportion of patients from the group who had at least one on-treatment TBL value of 1.5 × ULN or greater on or before the time point.](6605653f3){#fig3}

![Pazopanib inhibition of UGT1A1 (**A**, duplicate data points) and OATP1B1 (**B**, triplicates). EG, the OATP1B1 probe substrate \[^3^H\]-estradiol 17*β*-[D]{.smallcaps}-glucuronide; IC~50~, half-maximal inhibitory concentration.](6605653f4){#fig4}

###### 

Polymorphisms evaluated in pazopanib-treated white patients with renal cell carcinoma

  **Gene**       **Polymorphism**      **rs number**  **Reference**
  ----------- ----------------------- --------------- -------------------------------------------------------------
  *CYP1A2*            −163C/A            rs762551     [Han *et al* (2002)](#bib11){ref-type="other"}
                      −729C/T           rs12720461    [Aklillu *et al* (2003)](#bib1){ref-type="other"}
  *CYP3A4*            −392A/G            rs2740574    [Rodriguez-Antona *et al* (2005)](#bib24){ref-type="other"}
  *CYP3A5*            6986A/G            rs776746     [Wong *et al* (2004)](#bib35){ref-type="other"}
                 27289C/A (T398N)       rs28365083    [Jounaidi *et al* (1996)](#bib14){ref-type="other"}
  *CYP2C8*        805A/T (I269F)        rs11572103    [Dai *et al* (2001)](#bib6){ref-type="other"}
                  1196A/G (K399R)       rs10509681     
                  792C/G (I264M)         rs1058930    [Bahadur *et al* (2002)](#bib4){ref-type="other"}
  *ABCB1*             −129T/C            rs3213619    [Kerb (2006)](#bib16){ref-type="other"}
                      1236T/C            rs1128503     
                2677G/T/A (A893S/T)      rs2032582     
                      3435C/T            rs1045642     
  *ABCG2*          34G/A (V12M)          rs2231137    [Mizuarai *et al* (2004)](#bib19){ref-type="other"}
                  421C/A (Q141K)         rs2231142    [Morisaki *et al* (2005)](#bib20){ref-type="other"}
  *UGT1A1*       TA6/TA7 (^\*^28)        rs8175347    [Bosma *et al* (1995)](#bib5){ref-type="other"}
                 −3279T/G (^\*^60)       rs4148323    [Sugatani *et al* (2002)](#bib31){ref-type="other"}
               211G/A (G71R) (^\*^6)     rs4124874    [Aono *et al* (1993)](#bib3){ref-type="other"}
  *SLCO1B1*       388A/G (N130D)         rs2306283    [Nozawa *et al* (2002)](#bib22){ref-type="other"}
                  521T/C (V174A)         rs4149056     
  *VEGFA*            −2578C/A            rs699947     [Schneider *et al* (2008)](#bib26){ref-type="other"}
                     −1498C/T            rs833061      
                     11154G/A            rs1570360     
                      −634G/C            rs2010963     
                      936C/T             rs3025039     
  *VEGFR2*        889G/A (V297I)         rs2305948     
                  1416A/T (Q472H)        rs1870377     
  *HIF1α*         1772C/T (P582S)       rs11549465    [Tanimoto *et al* (2003)](#bib32){ref-type="other"}
                  1790G/A (A588T)       rs11549467     

###### 

Demographic and baseline characteristics for patients in the PGx study

  **Characteristics**                                  **Study 1 (*n*=116)**   **Study 2 (*n*=130)**
  ---------------------------------------------------- ----------------------- -----------------------
  Age, mean years (s.d.)                               61.1 (10.2)             60.3 (9.1)
  Male gender, *n* (%)                                 78 (67)                 93 (72)
  BMI, mean (s.d.)                                     28.5 (6.4)              27.1 (5.1)
  Liver metastases, yes (%)                            21 (18)^a^              34 (26)
                                                                                
  *ECOG, n (%)*                                                                
   0                                                   74 (64)                 46 (35)
   1                                                   42 (36)                 84 (65)
                                                                                
  *MSKCC risk category, n (%)*                                                 
   Favourable                                          53 (46)                 51 (39)
   Intermediate                                        45 (39)                 72 (55)
   Poor                                                3 (3)                   2 (2)
   Unknown                                             15 (13)                 5 (4)
                                                                                
  Earlier nephrectomy, *n* (%)                         97 (84)                 116 (89)
  Baseline ALT × ULN, median (25th, 75th percentile)   0.5 (0.3, 0.6)          0.4 (0.3, 0.7)
  Baseline TBL × ULN, median (25th, 75th percentile)   0.5 (0.3, 0.6)          0.5 (0.3, 0.6)

Abbreviations: ALT=alanine aminotransferase; BMI=body mass index; ECOG PS=Eastern Cooperative Oncology Group performance status; MSKCC=Memorial Sloan-Kettering Cancer Center; PGx=pharmacogenetics; s.d.=standard deviation; TBL=total bilirubin; ULN=upper limit of normal range.

Two patients from Study 1 did not have information for baseline liver metastases.
